<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689559</url>
  </required_header>
  <id_info>
    <org_study_id>D3691C00001</org_study_id>
    <secondary_id>EudraCt nr 2008-000310-74</secondary_id>
    <nct_id>NCT00689559</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects</brief_title>
  <official_title>A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or
      not, i.e. show the same or altered plasma concentration profiles when co-administered
      compared to administered alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK variables</measure>
    <time_frame>Frequent sampling occasions during</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, blood pressure, pulse, safety lab)</measure>
    <time_frame>During the whole treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3480 + Aripiprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo + Aripiprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>AZD3480 capsules qd, oral, 22 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo qd, 12 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>single dose on day 5</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed written informed consent

          -  Clinically normal physical findings and laboratory values

        Exclusion Criteria:

          -  Clinically significant illness or clinically relevant trauma within three weeks before
             the first dose

          -  History of clinically significant disease

          -  Use of prescribed medication during the 2 weeks before administration of the first
             dose of investigational product
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lennart Jeppsson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Södertälje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ctril Clarke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Development Solutions UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>June 30, 2009</last_update_submitted>
  <last_update_submitted_qc>June 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hans-Göran Hårdemark, MD, PhD, Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Södertälje</organization>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>AZD3480</keyword>
  <keyword>Aripiprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

